Recent Company News

• 04:27 AM ET Aug 06, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:04 AM ET Sep 15, 2025
  

  Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs agreements with Leading local Clinical Partners (€0.17, 0.00)

• 01:03 AM ET Sep 11, 2025
  

  Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia (€0.17, 0.00)

• 01:02 AM ET Sep 03, 2025
  

  Biophytis obtains EMA authorization to launch its Phase 2 clinical trial of BIO101 in obesity (€0.18, 0.00)

• 01:06 AM ET Sep 01, 2025
  

  Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil (€0.17, 0.00)

• 01:04 AM ET Aug 28, 2025
  

  Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial (€0.17, 0.00)